Segall Bryant & Hamill’s Jazz Pharmaceuticals JAZZ Stock Holding History

Segall Bryant & Hamill’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,200	Closed	-$279K	–	760
2021 Q4	$279K	Sell	2,200 -60	-3%	-$7.88K	﹤0.01%	560
2021 Q3	$296K	Sell	2,260 -35	-2%	-$5.29K	﹤0.01%	698
2021 Q2	$408K	Sell	2,295 -6	-0.3%	-$1.04K	﹤0.01%	648
2021 Q1	$377K	Buy	2,301 +6	+0.3%	+$987	﹤0.01%	689
2020 Q4	$379K	Hold	2,295	–	–	﹤0.01%	622
2020 Q3	$327K	Hold	2,295	–	–	﹤0.01%	614
2020 Q2	$255K	Hold	2,295	–	–	﹤0.01%	714
2020 Q1	$229K	Hold	2,295	–	–	﹤0.01%	720
2019 Q4	$340K	Hold	2,295	–	–	0.01%	718
2019 Q3	$293K	Hold	2,295	–	–	﹤0.01%	738
2019 Q2	$327K	Sell	2,295 -50	-2%	-$6.72K	﹤0.01%	727
2019 Q1	$335K	Hold	2,345	–	–	0.01%	720
2018 Q4	$291K	Hold	2,345	–	–	0.01%	740
2018 Q3	$394K	Hold	2,345	–	–	0.01%	723
2018 Q2	$404K	Buy	+2,345	New	+$383K	0.01%	708

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Segall Bryant & Hamill's JAZZ Position: Q1 2022 in Review

Segall Bryant & Hamill sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2022, closing a stake of 2,200 shares — an estimated $279K sold.

Segall Bryant & Hamill first reported a position in JAZZ in Q2 2018 and held it in 15 quarters. The position peaked at $408K in Q2 2021. 462 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

Segall Bryant & Hamill reported no remaining Jazz Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Segall Bryant & Hamill sold 2,200 Jazz Pharmaceuticals shares in Q1 2022, an estimated $279K.
Segall Bryant & Hamill first reported a position in Jazz Pharmaceuticals in Q2 2018 and held it in 15 quarters.
Segall Bryant & Hamill's Jazz Pharmaceuticals position peaked at $408K in Q2 2021.
462 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on Segall Bryant & Hamill's 13F filing for Q1 2022, filed 13 May 2022.